Treatment and prognosis of hepatocellular carcinoma: A population based study in France

Borie, F.; Bouvier, Anne–Marie; Herrero, Astrid; Faivre, Jean; Launoy, Guy; Delafosse, Patricia; Velten, Michel; Buémi, Antoine; Peng, Jun; Grosclaude, Pascale; Trétarre, Brigitte

doi:10.1002/jso.21159

Cited by 75 publications

(65 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While Milan or UCSF criteria were not fully implemented during period A (2000)(2001)(2002)(2003), there was no change over time that suggested any difference. Similar figures are reported in other surveys [20]. In a study where 28% of the tumours were detected by screening, 25% were treated with a curative aim [21] -the same results should be achievable in a Swedish population with liver disease if every person were to be thoroughly screened.…”

Section: Discussionsupporting

confidence: 79%

Staging and therapy for patients with hepatocellular cancer in a defined population from 2000 to 2011 – active palliative treatment improved overall survival

et al. 2015

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 79%

Staging and therapy for patients with hepatocellular cancer in a defined population from 2000 to 2011 – active palliative treatment improved overall survival

et al. 2015

View full text Add to dashboard Cite

“…This is consistent with the findings reported by Turakhia et al (29), which indicated that HSP27 reduced the doxorubicin-induced toxicity in cardiac cells by enhancing superoxide dismutase activity, and therefore protected the integrity of aconitases from superoxide-induced inactivation (29). According to the results of previous studies, the inhibition of HSPs has been established to have an impact on the growth of several malignant cell lines, including breast cancer (30) and leukemia (31). Furthermore, HSPs are known to form a complex with mutant p53, which allows tumor cells to bypass normal mechanisms of the cell cycle arrest.…”

Section: A B Csupporting

confidence: 89%

Heat shock protein 27 promotes cell proliferation through activator protein-1 in lung cancer

Zhang

Huang

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. Heat shock protein 27 (HSP27) is an important regulator involved in the development of lung cancer. However, limited evidence exists concerning the underlying molecular mechanisms of its action. The results of the present study revealed that HSP27 was highly expressed in the lung cancer tissues of mice. In an in vitro model, the overexpression of HSP27 promoted cell proliferation, while HSP27 knockdown inhibited cell proliferation. HSP27 promoted cell proliferation in vitro by directly upregulating the expression of HSP27 target genes, which required the activation of the activator protein-1 (AP-1) signaling pathway. This was evaluated by the phosphorylation status of an important pathway component, c-Jun in lung cancer tissue and cells. These results suggested that HSP27 has a promotional role in lung cancer, and therefore indicated a novel mechanism involving lung cancer cell proliferation, which may underlie poor responses to therapy. Therefore, HSP27 may be a suitable therapeutic target for the treatment of lung cancer. IntroductionLung cancer is the leading cause of cancer-associated mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for ~85% of all mortalities associated with lung cancer. The overall five-year survival rate for patients remains poor (1-3). The poor prognoses of lung cancer patients primarily result from early relapse, metastasis and unsuccessful responses to treatment strategies, including surgery, chemotherapy and radiotherapy (4-6). In addition, the lack of effective prognostic biomarkers that are able to predict treatment response and prognosis affects treatment regimens and patient outcomes.Heat shock proteins (HSPs) are a large family of proteins that function as molecular chaperones under physiological conditions (7). The ability of radiofrequency ablation to induce the expression of HSPs, including HSP70, in small animal models suggests that HSPs may be involved in rescuing damaged cells in close proximity to the ablation zone and, therefore, limiting the therapeutic effects (8,9). In addition, HSPs have been identified to promote carcinogenesis by inhibiting apoptosis (10-14) and enhancing resistance to treatment (15,16). However, it has been established that HSPs function differently in different tumors (10,15).HSP27 is a 27-kDa protein that regulates apoptosis by interacting with key components of apoptotic signaling pathways, particularly those involved in the activation of caspases. Increasing evidence has indicated that HSP27 may play an important role in cancer (17). The expression of HSP27 has been associated with poor prognoses in ovarian (18), breast (10,19), gastric (20) and prostate cancers (21), as well as in osteoscarcomas (14). In addition, HSP27 has been reported to be associated with poor prognoses in patients with lung cancer (22). However, whether the expression of HSP27 has a prognostic role in lung cancer remains controversial. Zimmermann et al (22) reported that the level of serum HSP27 was positively correlated with advanced lung...

show abstract

“…Standard treatments for localized HCC include surgical resection, liver transplantation,1, 2 radiofrequency ablation (RFA),3, 4 and transcatheter arterial chemoembolization (TACE) 5, 6, 7. Treatment eligibility is dependent on patient and tumor conditions.…”

Section: Introductionmentioning

confidence: 99%

Progressive hypofractionated carbon‐ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials

Kasuya

Kato²,

Yasuda

et al. 2017

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe objective of this study was to evaluate the safety and efficacy of carbon‐ion radiotherapy (CIRT) in patients with hepatocellular carcinoma (HCC) with stepwise dose escalation and hypofractionation in 2 combined prospective trials.METHODSSequential phase 1/2 (protocol 9603) and phase 2 (protocol 0004) trials were conducted for patients with histologically proven HCC. The phase 1 component of protocol 9603 was a dose‐escalation study; CIRT was delivered in 12, 8, or 4 fractions. After determination of the recommended dose, 2 phase 2 trials were performed in an expanded cohort, and the data were pooled to analyze toxicity, local control, and overall survival.RESULTSIn the phase 1 component of protocol 9603, 69.6, 58.0, and 52.8 Gy (relative biological effectiveness [RBE]) in 12, 8, and 4 fractions, respectively, constituted the maximum tolerated doses, and 52.8 Gy (RBE) in 4 fractions was established as the recommended dose regimen for the 2 phase 2 studies. In 124 patients with a total of 133 lesions, few severe adverse effects occurred, and local‐control and overall survival rates at 1, 3, and 5 years were 94.7% and 90.3%, 91.4% and 50.0%, and 90.0% and 25.0%, respectively; this included 1‐, 3‐, and 5‐year local‐control rates of 97.8%, 95.5%, and 91.6%, respectively, in the phase 2 study. In a multivariate analysis, Child‐Pugh class B and the presence of a tumor thrombus were significant factors for mortality.CONCLUSIONSThe safety and efficacy of CIRT in 12, 8, and 4 fractions were confirmed, with 52.8 Gy (RBE) in 4 fractions established as the recommended treatment course for eligible HCC patients. Cancer 2017;123:3955‐65. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

show abstract

Treatment and prognosis of hepatocellular carcinoma: A population based study in France

Abstract: HCC with and without cirrhosis has a poor prognosis with the majority of patients receiving palliative treatments, the efficiency of which is very limited. Considerable efforts are needed to develop primary and secondary prevention.

Cited by 75 publications

References 25 publications

Staging and therapy for patients with hepatocellular cancer in a defined population from 2000 to 2011 – active palliative treatment improved overall survival

Staging and therapy for patients with hepatocellular cancer in a defined population from 2000 to 2011 – active palliative treatment improved overall survival

Heat shock protein 27 promotes cell proliferation through activator protein-1 in lung cancer

Progressive hypofractionated carbon‐ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials

Contact Info

Product

Resources

About